Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FJKUT
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $65,000
Award facts
- Contract value 100% obligated
- $64,999.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at approximately $65K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. This firm fixed-price delivery order, issued on October 30, 2025, with an ultimate completion date of November 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense healthcare facilities globally.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity demonstrating consistent performance across multiple therapeutic categories and product lines. The company's comprehensive product portfolio includes specialty pharmaceuticals, biologics, oncology treatments, and medical consumables, with delivery orders ranging from minimal purchases to significant awards exceeding $115K. The PPV-G GEN V IDC, awarded November 13, 2025, with a ceiling value of $499.999 billion and completion date of December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor supporting the Department of Defense military medical system's diverse and specialized pharmaceutical requirements.
Quick answers
Who was awarded contract SPE2DB26FJKUT?
SPE2DB26FJKUT was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 30, 2025.
How much is contract SPE2DB26FJKUT worth?
The government has obligated $65,000 on SPE2DB26FJKUT.
Is contract SPE2DB26FJKUT an order under another contract?
Yes. SPE2DB26FJKUT is a delivery order under SPE2DB24D9802, an indefinite delivery contract.
Was contract SPE2DB26FJKUT competed?
The extent of competition for SPE2DB26FJKUT was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award